Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.
Dummer R. et al, (2025), Clin Cancer Res
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2025), Nat Commun, 16
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner JF. et al, (2025), Blood
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
Di Giovannantonio M. et al, (2025), Cell Genom, 5
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K. et al, (2025), Future Oncol, 21, 195 - 200
The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.
Greene J. et al, (2025), Cancer Control, 32
Molecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.
Harrison CN. et al, (2024), Future Oncol, 20, 3365 - 3376
INCA033989: the first shot on goal for MPNs?
Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
O'Sullivan J. et al, (2024), British Journal of Haematology
Redefining PD1 as a guardian of stem-like T cells.
Jackson M. and Parkes EE., (2024), Nat Rev Immunol